Robert Willette
Interim Chief Scientific Officer at APIE Therapeutics- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Experience
-
APIE Therapeutics
-
United States
-
Pharmaceutical Manufacturing
-
1 - 100 Employee
-
Interim Chief Scientific Officer
-
Jan 2021 - Present
Cary, North Carolina, United States info@apie-therapeutics.com
-
-
-
Chimeron Bio
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Chimeron SAB member
-
Mar 2020 - Present
Philadelphia, Pennsylvania, United States
-
-
-
ImmunoMet Therapeutics, Inc.
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Senior Scientific Advisor
-
Jul 2019 - Present
Houston, TX
-
-
Interim CSO ImmunoMet
-
Oct 2019 - May 2020
Houston, Texas, United States
-
-
-
-
President
-
May 2018 - Present
Greater Philadelphia Area Providing consulting services to pharma, biotech, foundations and investors.
-
-
-
-
Acting CSO
-
Jun 2019 - Mar 2020
Berwyn, PA
-
-
-
-
Vice President, Sr Fellow, Heart Failure and Renal Discovery Unit Head,
-
Feb 1987 - Apr 2018
Upper Merion, PA I received my doctoral degree from the Department of Pharmacology at Rutgers University, School of Medicine and Dentistry in New Jersey, where I studies the central control of circulation and pulmonary function. I pursued postdoctoral training in cardiopulmonary biology at the Veterans Administration in NJ and the Department of Neurosurgery at Rutgers University and neurobiology at the Weill Medical College, Cornell University. Since that time, I have been employed for 30 years in the… Show more I received my doctoral degree from the Department of Pharmacology at Rutgers University, School of Medicine and Dentistry in New Jersey, where I studies the central control of circulation and pulmonary function. I pursued postdoctoral training in cardiopulmonary biology at the Veterans Administration in NJ and the Department of Neurosurgery at Rutgers University and neurobiology at the Weill Medical College, Cornell University. Since that time, I have been employed for 30 years in the pharmaceutical industry as a discovery pharmacologist and have authored >150 original peer reviewed research papers. During this time I have worked on many discovery projects in the cardiopulmonary, cerebrovascular and renal space and received the AHA Robert Seikert Award for outstanding stroke research and the George Koelle Award for contributions in Pharmacology. I have served as President of the Mid-Atlantic Pharmacology Society and as a Thomas Jefferson University adjunct professor, Nephcure Foundation scientific advisor, and currently serve as an industry mentor at the Perelman School of Medicine at University of Pennsylvania in the Institute of Translational Medicine. I am currently employed as VP, unit head and senior fellow in the Heart Failure & Renal Discovery Performance Unit at GSK. I am very excited about leading a new discovery alliance in partnership with Idera in Boston to explore a new gene silencing modality for the treatment of kidney disease. Finally, during my long career in drug discovery I have had the very great privilege of working with first-rate colleagues at all levels that have taught and inspired me. Show less
-
-
Education
-
UMDNJ-Rutgers
Doctor of Philosophy (PhD), Pharmacology